EICHORCondition: HR+/HER2- Breast Cancer · Sponsor: First Affiliated Hospital of Zhejiang University
Sponsor, CRO or site team? See where this study is running → — listed sites, countries and recruiting context. Everything below is written for patients and caregivers.
This study is a prospective, single arm, multi-center phase II clinical trial. The primary study objective is to evaluate the pathologic complete response（PCR）and RCB0-1 ratio of neodjuvant treatment of HR+/HER2- breast cancer with Toripalimab combined with neoadjuvant chemotherapy and sequential Toripalimab monoclonal antibody, including the incidences and types of adverse events. The secondary study objective is to observe and evaluate the disease-free survival (DFS), Progression-Free-Survival (PFS ),and Objective Response Rate(ORR)
This description comes directly from the study's public registry record.
Zhijun Dai · +86 157 0581 9132 · dzj0911@126.com
Youyi Chen · +86 157 5751 5017
Always discuss trial participation with your own doctor first.
| The First Affiliated Hospital of Zhejiang University | Hangzhou, China | Recruiting |
| Zhejiang Cancer Hospital | Hangzhou, China | Recruiting |
| Harbin Medical University Cancer Hospital | Harbin, China | Not Yet Recruiting |
| The First Affiliated Hospital of Anhui Medical University | Hefei, China | Not Yet Recruiting |
| Jinhua Municipal Central Hospital | Jinhua, China | Not Yet Recruiting |
| Nanchang People's Hospital | Nanchang, China | Not Yet Recruiting |
| Zhongshan Hospital, Fudan University | Shanghai, China | Not Yet Recruiting |
| Xinjiang Medical University Affiliated Cancer Hospital | Ürümqi, China | Not Yet Recruiting |
| Shaanxi Provincial Cancer Hospital | Xi'an, China | Not Yet Recruiting |
| The Second Affiliated Hospital of Xi'an Jiaotong University | Xi'an, China | Recruiting |
| The First Affiliated Hospital of Zhengzhou University | Zhengzhou, China | Not Yet Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice. By subscribing you agree to our Terms of Use and Privacy Policy.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06611813